BioPharma Dive September 26, 2024
Even in a selective investment climate, the firm is “in the ‘taking lots of risk’ mode,” according to co-founder Robert Nelsen.
Arch Venture Partners, a prominent creator of biotechnology startups, has raised more than $3 billion for its 13th fund, the firm announced Thursday.
The fundraise comes only two years after Arch secured a similar-sized haul that, at the time, was its largest to date. As it has in the past, the 38-year-old firm intends to use that cash to bet on cutting-edge science it believes can change healthcare. Arch has been a big proponent of the use of high-powered computing tools in drug discovery, for instance, and in a statement, co-founder and managing director Robert Nelsen noted how...
Today's Sponsors
Today's Sponsor